AVRO - Protalix Could Claim Substantial Global Market Share In Fabry Disease October, 01 2020 02:54 AM AVROBIO Inc. Strong need for improved enzyme replacement therapies. Protalix's deliberately engineered ERT appears to fill this unmet need. Significant potential for share price appreciation. For further details see: Protalix Could Claim Substantial Global Market Share In Fabry Disease